trial

Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics

NCTId NCT01972711
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 105 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2015-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
105 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-03
Primary completion
2015-07
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
UlotarontAmisulpride

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor

Sites

2 total
Headington, United KingdomManchester, United Kingdom

Facts & assertions

4 sourced
Enrollment
105
Phase
PHASE1
Primary Completion Date
2015-07
Status
COMPLETED
relationships
The graph out of here
drug
Ulotaront
drug
Amisulpride
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication